Finanzas de Xenetic Biosciences Inc (XBIO)XBIOXenetic Biosciences Inc

Evaluating the bottom line, Xenetic Biosciences Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -147.09%, while the net margin is -140.73%. These profitability ratios, combined with a Return on Equity (ROE) of -47.05%, provide a clear picture of how effectively XBIO converts its operational activities into shareholder value.

In the context of the broader market, XBIO competes directly with industry leaders such as SKYE and MGRX. With a market capitalization of $4.38M, it holds a significant position in the sector. When comparing efficiency, XBIO's gross margin of 100.00% stands against SKYE's N/A and MGRX's -342.77%. Such benchmarking helps identify whether Xenetic Biosciences Inc is trading at a premium or discount relative to its financial performance.

Xenetic Biosciences has shown a significant reduction in net losses, with a Q1 2026 net loss of $0.46 million compared to $0.9 million in the same period of 2025. However, the company continues to operate at a loss, with a total net loss of approximately $2.7 million for FY 2025. Gross margins remain high at 100%, but net margins are negative, indicating ongoing financial struggles despite some revenue growth.